Prasad S. Adusumilli, MD, FACS, deputy chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center, discusses the current role of chimeric antigen receptor (CAR) T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Investigators are currently translating data from preclinical trials to determine the potential role of CAR T cells in solid tumors. Unlike in the hematologic space, there are several hurdles to overcome in solid tumors that are specific to the solid tumor microenvironment, Adusumilli says.

At this time, investigators are focusing on how to overcome each of the hurdles to determine the role of CAR T-cell therapy in the treatment landscape of solid tumors.

For example, one hurdle to overcome is that T cells are unable to enter the tumor with solid tumors, especially when the T cells are administered intravenously, Adusumilli explains.

2020 International Congress on Hematologic Malignancies

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


CAR T-cell Therapy

 CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment. 

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Dr. Adusumilli on the Development of CAR T Cells in Solid Tumors